Illumina Cuts Guidance on Threat From Tariffs and China Ban (1)

Illumina Inc. cut its full-year adjusted profit guidance for the second time in three months as it grapples with the impact of tariffs and China banning imports of its gene-sequencing machines.

The maker of DNA sequencing machines now expects adjusted earnings of $4.20 per share to $4.30 per share for the fiscal year, it said in a statement. That’s a reduction from its March forecast of $4.50 a share, which was down from the $4.50 per share to $4.65 a share it offered in February.

Illumina’s shares declined 2.7% in after-hours trading. They have fallen 40% so far this year, ...